[go: up one dir, main page]

RU2002129569A - NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS - Google Patents

NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS Download PDF

Info

Publication number
RU2002129569A
RU2002129569A RU2002129569/15A RU2002129569A RU2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569/15 A RU2002129569/15 A RU 2002129569/15A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A
Authority
RU
Russia
Prior art keywords
hypertension
renal failure
pharmaceutically acceptable
combination
restenosis
Prior art date
Application number
RU2002129569/15A
Other languages
Russian (ru)
Inventor
Роналд Эдуард СТИЛ (US)
Роналд Эдуард СТИЛ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2002129569A publication Critical patent/RU2002129569A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1. Применение фармацевтической композиции, содержащей (I) ингибитор альдостеронсинтазы или его фармацевтически приемлемую соль индивидуально или в сочетании с (II) антагонистом AT1-рецептора или антагонистом АТ1-рецептора в сочетании с диуретиком или в каждом случае с его фармацевтически приемлемой солью и (III) фармацевтически приемлемый носитель, для предупреждения, замедления развития, лечения болезни или состояния, выбранных из группы, включающей (а) гипертензию, застойную сердечную недостаточность, почечную недостаточность, прежде всего хроническую почечную недостаточность, рестеноз после чрезкожной внутрипросветной ангиопластики и рестеноз после хирургической операции, связанной с шунтированием коронарной артерии, (б) атеросклероз, устойчивость к инсулину и синдром X, сахарный диабет типа 2, ожирение, нефропатию, почечную недостаточность, например, хроническую почечную недостаточность, гипотиреоидизм, состояние после инфаркта миокарда (МИ), коронарные заболевания сердца, гипертензию, связанную с возрастом, семейную дислипидемическую гипертензию, повышенное образование коллагена, фиброз и гипертензию, возникающую после ремоделирования (антипролиферативное действие комбинации), при этом все указанные заболевания или состояния связаны с гипертензией или не связаны с ней, и (в) эндотелиальную дисфункцию, сопровождающуюся или не сопровождающуюся гипертензией.1. The use of a pharmaceutical composition comprising (I) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof individually or in combination with (II) an AT 1 receptor antagonist or an AT 1 receptor antagonist in combination with a diuretic or, in each case, a pharmaceutically acceptable salt thereof and (III) a pharmaceutically acceptable carrier for preventing, slowing down, treating a disease or condition selected from the group consisting of (a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous intraluminal angioplasty, and restenosis after surgery for coronary artery bypass grafting, (b) atherosclerosis, insulin resistance and Syndrome X, type 2 diabetes mellitus, obesity, nephropathy, renal failure, for example, chronic renal insufficiency, hypothyroidism, the state after myocardial infarction (MI), coronary heart disease, age-related hypertension, familial dyslipidemic hypertension, increased image collagen formation, fibrosis, and hypertension that occurs after remodeling (the antiproliferative effect of the combination), while all these diseases or conditions are associated with or are not associated with hypertension, and (c) endothelial dysfunction, with or without hypertension. 2. Применение по п.1, где антагонист AT1-рецептора выбирают из группы, включающей валсартан, лосартан, кандесартан, эпросартан, ирбесартан, саприсартан, тасосартан, телмисартан, соединение, обозначенное как Е-1477, которое имеет следующую формулу:2. The use according to claim 1, where the AT 1 receptor antagonist is selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, a compound designated as E-1477, which has the following formula:
Figure 00000001
Figure 00000001
 соединение, обозначенное как SC-52458, которое имеет следующую формулу:a compound designated as SC-52458, which has the following formula:
Figure 00000002
Figure 00000002
 и соединение, обозначенное как ZD-8731, которое имеет следующую формулу:and the compound designated as ZD-8731, which has the following formula:
Figure 00000003
Figure 00000003
 или в каждом случае их фармацевтически приемлемые соли.or in each case their pharmaceutically acceptable salts. 3. Применение по п.2, где антагонист AT1-рецептора представляет собой валсартан или его фармацевтически приемлемую соль.3. The use of claim 2, wherein the AT 1 receptor antagonist is valsartan or a pharmaceutically acceptable salt thereof. 4. Применение по любому из пп.1-3, где ингибитор альдостеронсинтазы выбирают из группы, включающей анастрозол, фадрозол (включая его (+)-энантиомер) и эксеместан, или в каждом случае, если это возможно, их фармацевтически приемлемые соли.4. The use according to any one of claims 1 to 3, wherein the aldosterone synthase inhibitor is selected from the group consisting of anastrozole, fadrozole (including its (+) enantiomer) and exemestane, or in each case, if possible, their pharmaceutically acceptable salts. 5. Применение по любому из пп.1-4, где ингибитор альдостеронсинтазы представляет собой (+)-энантиомер гидрохлорида фадрозола формулы5. The use according to any one of claims 1 to 4, wherein the aldosterone synthase inhibitor is the (+) - enantiomer of fadrosol hydrochloride of the formula
Figure 00000004
Figure 00000004
 6. Применение по любому из пп.1-5, где диуретик представляет собой гидрохлортиазид.6. The use according to any one of claims 1 to 5, where the diuretic is hydrochlorothiazide. 7. Применение фармацевтической композиции, содержащей ингибитор альдостеронсинтазы или его фармацевтически приемлемую соль, для приготовления лекарственного средства, предназначенного для предупреждения, замедления развития, лечения болезни или состояния, выбранных из группы, включающей (α) гипертензию, застойную сердечную недостаточность, почечную недостаточность, прежде всего хроническую почечную недостаточность, рестеноз после чрезкожной внутрипросветной ангиопластики и рестеноз после хирургической операции, связанной с шунтированием коронарной артерии, (β) атеросклероз, устойчивость к инсулину и синдром X, сахарный диабет типа 2, ожирение, нефропатию, почечную недостаточность, например, хроническую почечную недостаточность, гипотиреоидизм, состояние после инфаркта миокарда (МИ), коронарные заболевания сердца, гипертензию, связанную с возрастом, семейную дислипидемическую гипертензию, повышенное образование коллагена, фиброз и гипертензию, возникающую после ремоделирования (антипролиферативное действие комбинации), при этом все указанные заболевания или состояния связаны с гипертензией или не связаны с ней, и (γ) эндотелиальную дисфункцию, сопровождающуюся или не сопровождающуюся гипертензией.7. The use of a pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention, retardation, treatment of a disease or condition selected from the group consisting of (α) hypertension, congestive heart failure, renal failure, previously total chronic renal failure, restenosis after percutaneous intraluminal angioplasty, and restenosis after shunt surgery coronary artery disease, (β) atherosclerosis, insulin resistance and X syndrome, type 2 diabetes mellitus, obesity, nephropathy, renal failure, for example, chronic renal failure, hypothyroidism, post-myocardial infarction (MI), coronary heart disease, hypertension, age-related familial dyslipidemic hypertension, increased collagen formation, fibrosis and hypertension that occurs after remodeling (antiproliferative effect of the combination), with all these diseases or thawing is associated with hypertension or not associated with it, and (γ) endothelial dysfunction, with or without hypertension. 8. Фармацевтическая композиция, содержащая (I) ингибитор альдостеронсинтазы или его фармацевтически приемлемую соль индивидуально или в сочетании с (II) антагонистом AT1-рецептора или антагонистом AT1-рецептора в сочетании с диуретиком или в каждом случае с его фармацевтически приемлемой солью и (III) фармацевтически приемлемый носитель, для предупреждения, замедления развития, лечения болезни или состояния, выбранных из группы, включающей (а) гипертензию, застойную сердечную недостаточность, почечную недостаточность, прежде всего хроническую почечную недостаточность, рестеноз после чрезкожной внутрипросветной ангиопластики и рестеноз после хирургической операции, связанной с шунтированием коронарной артерии, (б) атеросклероз, устойчивость к инсулину и синдром X, сахарный диабет типа 2, ожирение, нефропатию, почечную недостаточность, например, хроническую почечную недостаточность, гипотиреоидизм, состояние после инфаркта миокарда (МИ), коронарные заболевания сердца, гипертензию, связанную с возрастом, семейную дислипидемическую гипертензию, повышенное образование коллагена, фиброз и гипертензию, возникающую после ремоделирования (антипролиферативное действие комбинации), при этом все указанные заболевания или состояния связаны с гипертензией или не связаны с ней, и (в) эндотелиальную дисфункцию, сопровождающуюся или не сопровождающуюся гипертензией.8. A pharmaceutical composition comprising (I) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof individually or in combination with (II) an AT 1 receptor antagonist or an AT 1 receptor antagonist in combination with a diuretic or, in each case, a pharmaceutically acceptable salt thereof and ( III) a pharmaceutically acceptable carrier for the prevention, retardation, treatment of a disease or condition selected from the group consisting of (a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous intraluminal angioplasty, and restenosis after surgery for coronary artery bypass grafting, (b) atherosclerosis, insulin resistance and X syndrome, type 2 diabetes mellitus, obesity, nephropathy, renal failure, for example, chronic renal failure , hypothyroidism, the state after myocardial infarction (MI), coronary heart disease, age-related hypertension, familial dyslipidemic hypertension, increased collagen formation gene, fibrosis, and hypertension that occurs after remodeling (the antiproliferative effect of the combination), while all these diseases or conditions are associated with or are not associated with hypertension, and (c) endothelial dysfunction, with or without hypertension. 9. Способ предупреждения, замедления развития, лечения болезни или состояния, выбранных из группы, включающей (а) гипертензию, застойную сердечную недостаточность, почечную недостаточность, прежде всего хроническую почечную недостаточность, рестеноз после чрезкожной внутрипросветной ангиопластики и рестеноз после хирургической операции, связанной с шунтированием коронарной артерии, (б) атеросклероз, устойчивость к инсулину и синдром X, сахарный диабет типа 2, ожирение, нефропатию, почечную недостаточность, например, хроническую почечную недостаточность, гипотиреоидизм, состояние после инфаркта миокарда (МИ), коронарные заболевания сердца, гипертензию, связанную с возрастом, семейную дислипидемическую гипертензию, повышенное образование коллагена, фиброз и гипертензию, возникающую после ремоделирования (антипролиферативное действие комбинации), при этом все указанные заболевания или состояния связаны с гипертензией или не связаны с ней, и (в) эндотелиальную дисфункцию, сопровождающуюся или не сопровождающуюся гипертензией, предусматривающий введение теплокровному животному, в том числе человеку, нуждающемуся в таком лечении, терапевтически эффективного количества ингибитора альдостеронсинтазы в свободной форме или в форме фармацевтически приемлемой соли.9. A method for preventing, slowing down, treating a disease or condition selected from the group consisting of (a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous intraluminal angioplasty, and restenosis after surgery bypass surgery coronary artery, (b) atherosclerosis, insulin resistance and Syndrome X, type 2 diabetes mellitus, obesity, nephropathy, renal failure, for example, chronic renal insufficiency, hypothyroidism, the condition after myocardial infarction (MI), coronary heart disease, age-related hypertension, familial dyslipidemic hypertension, increased collagen formation, fibrosis and hypertension that occurs after remodeling (antiproliferative effect of the combination), while all these diseases or conditions associated with hypertension or not associated with it, and (c) endothelial dysfunction, accompanied or not accompanied by hypertension, involving the introduction of warm-blooded The animal, including a human, in need of such treatment a therapeutically effective amount of an aldosterone synthase inhibitor in free form or in pharmaceutically acceptable salt form. 10. Способ по п.9, дополнительно предусматривающий введение терапевтически эффективного количества антагониста At1-рецептора или антагониста AT1-рецептора в сочетании с диуретиком в каждом случае в свободной форме или в форме фармацевтически приемлемой соли.10. The method of claim 9, further comprising administering a therapeutically effective amount of an At 1 receptor antagonist or an AT 1 receptor antagonist in combination with a diuretic, in each case, in free form or in the form of a pharmaceutically acceptable salt.
RU2002129569/15A 2000-04-12 2001-04-10 NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS RU2002129569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674200P 2000-04-12 2000-04-12
US60/196,742 2000-04-12

Publications (1)

Publication Number Publication Date
RU2002129569A true RU2002129569A (en) 2004-03-27

Family

ID=22726655

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002129569/15A RU2002129569A (en) 2000-04-12 2001-04-10 NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS

Country Status (19)

Country Link
EP (1) EP1282410A2 (en)
JP (1) JP2003530343A (en)
KR (1) KR20020089437A (en)
CN (1) CN1422152A (en)
AR (1) AR032316A1 (en)
AU (2) AU2001273938B2 (en)
BR (1) BR0110079A (en)
CA (1) CA2405895A1 (en)
HU (1) HUP0301335A3 (en)
IL (1) IL152081A0 (en)
MX (1) MXPA02010091A (en)
NO (1) NO20024920L (en)
NZ (1) NZ521855A (en)
PE (1) PE20020082A1 (en)
PL (1) PL358459A1 (en)
RU (1) RU2002129569A (en)
SK (1) SK14612002A3 (en)
WO (1) WO2001076574A2 (en)
ZA (1) ZA200208204B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518611A (en) * 2000-07-27 2004-06-24 ファルマシア・コーポレーション Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003292775A1 (en) * 2002-12-27 2004-07-29 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
SE0300988D0 (en) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
ITTO20040760A1 (en) * 2004-11-03 2005-02-03 Uni Degli Studi Del Piemonte USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EP1853261B1 (en) 2005-03-03 2017-01-11 Universität des Saarlandes Selective inhibitors of human corticosteroid synthases
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP5420761B2 (en) 2009-05-28 2014-02-19 ノバルティス アーゲー Substituted aminopropionic acid derivatives as neprilysin inhibitors
MX2011012627A (en) 2009-05-28 2011-12-14 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2683350T3 (en) 2011-07-08 2018-09-26 Novartis Ag Method to treat atherosclerosis in subjects with high triglycerides
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
PE20151666A1 (en) 2013-02-14 2015-11-19 Novartis Ag SUBSTITUTE DERIVATIVES OF BISPHENYL BUTANOIC PHOSPHONE ACID AS INHIBITORS OF NEP
TW201536814A (en) 2013-07-25 2015-10-01 Novartis Ag Synthetic cyclic polypeptides for the treatment of heart failure
PE20160991A1 (en) 2013-07-25 2016-10-15 Novartis Ag BIOCONJUGATES OF SYNTHETIC APELLIN POLYPEPTIDES
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
IL301471B2 (en) * 2016-10-27 2025-02-01 Damian Pharma Ag Aldosterone synthase inhibitor
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
SG11202010906XA (en) * 2018-05-03 2020-12-30 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
CN113166204B (en) 2018-11-27 2025-01-28 诺华股份有限公司 Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
WO2024241229A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative
EP0930876B2 (en) * 1996-07-22 2010-07-07 Renovo Limited Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
PT1096932E (en) * 1998-07-10 2007-09-21 Novartis Pharma Ag Antihypertensive combination of valsartan and calcium channel blocker

Also Published As

Publication number Publication date
CN1422152A (en) 2003-06-04
AU2001273938B2 (en) 2005-03-03
IL152081A0 (en) 2003-05-29
CA2405895A1 (en) 2001-10-18
AR032316A1 (en) 2003-11-05
KR20020089437A (en) 2002-11-29
WO2001076574A2 (en) 2001-10-18
HUP0301335A2 (en) 2003-08-28
NZ521855A (en) 2004-10-29
NO20024920L (en) 2002-11-27
EP1282410A2 (en) 2003-02-12
AU7393801A (en) 2001-10-23
HUP0301335A3 (en) 2006-02-28
SK14612002A3 (en) 2003-05-02
MXPA02010091A (en) 2003-02-12
WO2001076574A3 (en) 2002-04-25
ZA200208204B (en) 2003-10-14
BR0110079A (en) 2002-12-31
JP2003530343A (en) 2003-10-14
PE20020082A1 (en) 2002-02-21
NO20024920D0 (en) 2002-10-11
PL358459A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
RU2002129569A (en) NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS
JP2005533023A5 (en)
KR100550167B1 (en) Antihypertensive Concomitant Formulations of Valsartan and Calcium Channel Blockers
US9592231B2 (en) Therapy for complications of diabetes
US6204281B1 (en) Method of treatment and pharmaceutical composition
CN1655819A (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
TW200406204A (en) Combination of organic compounds
RU2002129558A (en) A COMBINATION AT LEAST OF TWO COMPOUNDS SELECTED FROM AT AN ANTAGONISTIC GROUPS, ACE RECEPTOR OR ACE INHIBITORS (ANGIOTENZIN-CONVERSING ENZYME) OR HMG-β-RESOURSE-RESIDUAL RESIDUES
JP2010507602A5 (en)
CN1474690A (en) Synergistic pharmaceutical combination comprising renin inhibitor for the treatment of cardiovascular diseases
RU2020113612A (en) TREATMENT OF FOCAL-SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
EP1487424B1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
RU2011105059A (en) Application of pyrimidylamino-benzamide derivatives for the treatment of fibrosis
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
RS65570B1 (en) Telmisartan for the prophylaxis or treatment of hypertension in cats
CN100558359C (en) Remedy for glomerular diseae
IL276474B2 (en) Substituted bisphenyl butanoic ester derivatives as nep inhibitors
RU2830555C2 (en) Telmisartan for treating hypertension in dogs
CN1589154A (en) Pharmaceutical composition containing angiotensin II receptor antagonist
JP2010031006A (en) Use of organic compound
CA2677822A1 (en) Antihypertensive drug combination

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070313